Naloxegol (Movantik)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain

Prior authorization criteria:

  • Patient is at least 18 years old, AND
  • OIC use is not due to cancer-related pain, AND
  • Patient does not have gastrointestinal obstruction or is at increased risk of recurrent obstruction, due to the potential for gastroinestinal perforation, AND
  • Will not be used concomitantly with strong CYP3A4 inhibitors, AND
  • Patient has tried and failed a stool softener plus a stimulant laxative and at least one other class of laxative

Dosing:

  • 25 mg once daily; if not tolerated, reduce to 12.5 mg once daily
  • Renal impairment (CLcr < 60 mL/min): 12.5 mg once daily; increase to 25mg once daily if tolerated and monitor for adverse reactions
  • Discontinue maintenance laxative therapy before starting Movantik; may resume laxatives if patients have OIC symptoms after taking Movantik for 3 days
  • Alteration in analgesic dosing regimen prior to starting Movantik is not required

Approval:

  • One year

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar